JP2000503115A - 細胞サンプルの試験方法 - Google Patents
細胞サンプルの試験方法Info
- Publication number
- JP2000503115A JP2000503115A JP9524115A JP52411597A JP2000503115A JP 2000503115 A JP2000503115 A JP 2000503115A JP 9524115 A JP9524115 A JP 9524115A JP 52411597 A JP52411597 A JP 52411597A JP 2000503115 A JP2000503115 A JP 2000503115A
- Authority
- JP
- Japan
- Prior art keywords
- cell
- sample
- cells
- volume
- permeability
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000010998 test method Methods 0.000 title description 2
- 210000004027 cell Anatomy 0.000 claims abstract description 190
- 239000012530 fluid Substances 0.000 claims abstract description 63
- 230000035699 permeability Effects 0.000 claims abstract description 51
- 230000008859 change Effects 0.000 claims abstract description 34
- 239000000725 suspension Substances 0.000 claims abstract description 26
- 210000000170 cell membrane Anatomy 0.000 claims abstract description 22
- 230000003204 osmotic effect Effects 0.000 claims abstract description 14
- 230000004044 response Effects 0.000 claims abstract description 6
- 239000007884 disintegrant Substances 0.000 claims abstract description 4
- 210000004369 blood Anatomy 0.000 claims description 41
- 239000008280 blood Substances 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 38
- 238000005259 measurement Methods 0.000 claims description 37
- 239000012528 membrane Substances 0.000 claims description 24
- 238000012360 testing method Methods 0.000 claims description 20
- 239000007788 liquid Substances 0.000 claims description 9
- 239000013256 coordination polymer Substances 0.000 claims description 8
- 230000001413 cellular effect Effects 0.000 claims description 6
- 230000006870 function Effects 0.000 claims description 5
- 101000957815 Culex pipiens Alpha-glucosidase Proteins 0.000 claims description 2
- 230000035899 viability Effects 0.000 claims description 2
- 239000000523 sample Substances 0.000 description 81
- 238000009826 distribution Methods 0.000 description 39
- 239000012895 dilution Substances 0.000 description 26
- 238000010790 dilution Methods 0.000 description 26
- 210000004379 membrane Anatomy 0.000 description 23
- 210000000601 blood cell Anatomy 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 210000003743 erythrocyte Anatomy 0.000 description 11
- 239000002245 particle Substances 0.000 description 9
- 239000004810 polytetrafluoroethylene Substances 0.000 description 9
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 9
- 238000012546 transfer Methods 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 239000004816 latex Substances 0.000 description 7
- 229920000126 latex Polymers 0.000 description 7
- 238000012937 correction Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000005540 biological transmission Effects 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000005684 electric field Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 210000002325 somatostatin-secreting cell Anatomy 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000012886 linear function Methods 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 241000224489 Amoeba Species 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 239000000592 Artificial Cell Substances 0.000 description 1
- 208000032589 Diaphragmatic Congenital Hernias Diseases 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000004164 analytical calibration Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002575 chemical warfare agent Substances 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 201000005890 congenital diaphragmatic hernia Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000008571 general function Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000000815 hypotonic solution Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/08—Investigating permeability, pore-volume, or surface area of porous materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N13/00—Investigating surface or boundary effects, e.g. wetting power; Investigating diffusion effects; Analysing materials by determining surface, boundary, or diffusion effects
- G01N13/04—Investigating osmotic effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
Landscapes
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.液体媒質中に懸濁した細胞サンプルの試験方法であって、前記細胞は液体 媒質の性質とは明確に異なる少なくとも1つの測定可能な性質を有し、前記サン プルは細胞サンプルの細胞透過性の測定値を決定するための分析に付され、 (a)サンプル細胞の懸濁液の第一アリコートをセンサーに通すこと、 (b)細胞の懸濁液の第一アリコートについての前記少なくとも1つの性質を測 定すること、 (c)細胞の第一アリコートについての前記性質の測定値を記録すること、 (d)サンプル細胞の懸濁液の第二アリコートに対して、細胞膜を横切る流体の 流れを生じさせることができる、細胞環境の少なくとも1つのパラメータを変更 して、それにより、細胞の少なくとも1つの性質を変えること、 (e)前記第二アリコートをセンサーに通すこと、 (f)変更した環境下において、細胞の懸濁液の前記少なくとも1つの性質を測 定すること、 (g)細胞の第二アリコートについての前記少なくとも1つの性質の測定値を記 録すること、 (h)工程(c)および(g)から得られたデータを、細胞環境の前記変更の程 度および前記少なくとも1つの性質の記録された測定値の変化の関数として比較 し、サンプルの細胞透過性の測定値を決定すること、 の工程を含む、方法。 2.液体媒質の性質とは異なる細胞の性質は、細胞の体積に関係 する性質であり、細胞の透過性の測定値は、変更した環境に応答して、サンプル 細胞膜を横切る流体の体積の測定値を得ることにより決定される、請求項1記載 の方法。 3.流体に細胞膜を横切らせ、それにより、細胞体積の変化を生じさせるため に崩壊剤が用いられる、請求項1または2記載の方法。 4.サンプル懸濁液を連続の浸透圧勾配に付す、請求項1〜3のいずれか1項 記載の方法。 5.測定値が細胞毎に記録される、請求項1〜4のいずれか1項記載の方法。 6.Cp速度が細胞透過性の測定値として決定される、請求項1〜5のいずれ か1項記載の方法。 7.透過性係数pkn が細胞透過性の測定値として決定され、nは正の整数で ある、請求項1〜5のいずれか1項記載の方法。 8.CpΔが細胞透過性の測定値として決定される、請求項1〜5のいずれか 1項記載の方法。 9.CPmax が細胞透過性の測定値として決定される、請求項1〜5のいずれ か1項記載の方法。 10.膜構造抵抗MSRが細胞透過性の測定値として決定される、請求項1〜 5のいずれか1項記載の方法。 11.Cpm1が細胞透過性の測定値として決定される、請求項1〜5のいず れか1項記載の方法。 12.請求項1〜11のいずれか1項記載の方法により、血液サンプルを試験 する工程を含む、血液バンクに保存された血液の生存性を決定するための方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9526684.7 | 1995-12-29 | ||
GBGB9526684.7A GB9526684D0 (en) | 1995-12-29 | 1995-12-29 | Method for testing a cell sample |
PCT/GB1996/003256 WO1997024598A1 (en) | 1995-12-29 | 1996-12-27 | Method for testing a cell sample |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2000503115A true JP2000503115A (ja) | 2000-03-14 |
JP2000503115A5 JP2000503115A5 (ja) | 2004-11-11 |
JP3650128B2 JP3650128B2 (ja) | 2005-05-18 |
Family
ID=10786180
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52411597A Expired - Lifetime JP3650128B2 (ja) | 1995-12-29 | 1996-12-27 | 細胞サンプルの試験方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US6668229B1 (ja) |
EP (1) | EP0870184B1 (ja) |
JP (1) | JP3650128B2 (ja) |
AT (1) | ATE220454T1 (ja) |
AU (1) | AU714947B2 (ja) |
CA (1) | CA2240471C (ja) |
DE (1) | DE69622282T2 (ja) |
GB (1) | GB9526684D0 (ja) |
WO (1) | WO1997024598A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007527540A (ja) * | 2004-03-05 | 2007-09-27 | ザ・リサーチ・ファンデーション・オブ・ステート・ユニバーシティ・オブ・ニューヨーク | 細胞の体積変化を測定するための方法及び装置 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU732426B2 (en) | 1998-12-29 | 2001-04-26 | Ian Basil Shine | A method of analysing a sample of free cells |
JP5294388B2 (ja) * | 2008-03-07 | 2013-09-18 | パナソニック株式会社 | 流量計測装置 |
CN105806766B (zh) * | 2016-04-19 | 2019-01-18 | 兰州大学 | 一种可测体变的柔性壁渗透仪 |
EP3891488A4 (en) * | 2018-12-05 | 2022-12-28 | Thomas Adam Shine | CELL SENSING TECHNOLOGIES AND METHODS OF USE THEREOF |
US20220211670A1 (en) * | 2019-04-22 | 2022-07-07 | Ian Basil Shine | Preventing and treating malaria |
US20230010400A1 (en) * | 2019-12-04 | 2023-01-12 | Ian Basil Shine | Improved methods and devices for measuring cell numbers and/or cell properties |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3502412A (en) | 1967-10-16 | 1970-03-24 | Abbott Lab | Method and apparatus for measuring osmotic fragility of red blood cells by constantly reducing the concentration of the saline solution suspending the cells |
CA988319A (en) | 1973-10-11 | 1976-05-04 | Tomas Hirschfeld | System for differentiating particles |
US3851246A (en) * | 1973-11-26 | 1974-11-26 | Us Navy | Method of predicting the post transfusion viability of preserved erythrocytes and other similar cells |
GB1481480A (en) | 1974-02-02 | 1977-07-27 | Kernforschungsanlage Juelich | Process and apparatus for increasing the permeability of the membrane of cells of organisms |
US4271001A (en) * | 1978-03-23 | 1981-06-02 | Asahi Kasei Kogyo Kabushiki Kaisha | Apparatus for measuring membrane characteristics of vesicles |
US4240027A (en) | 1978-08-31 | 1980-12-16 | The United States Of America As Represented By The Secretary Of The Army | Electromagnetic method for the noninvasive analysis of cell membrane physiology and pharmacology |
IT1105662B (it) | 1978-09-07 | 1985-11-04 | Salus Istituto Diagnostico Di | Apparecchiatura per studiare e fenomeni della emocoagulazione e dell'aggregazione delle piastrine |
US4298836A (en) | 1979-11-23 | 1981-11-03 | Coulter Electronics, Inc. | Particle shape determination |
US4278936A (en) | 1980-02-05 | 1981-07-14 | Coulter Electronics, Inc. | Biological cell parameter change test method and apparatus |
US4374644A (en) * | 1981-04-06 | 1983-02-22 | Coulter Electronics, Inc. | Blood cell volume monitoring |
US4535284A (en) * | 1981-07-10 | 1985-08-13 | Coulter Electronics, Inc. | High and low frequency analysis of osmotic stress of cells |
DE3215719C2 (de) | 1982-04-28 | 1984-01-26 | Holger Dr. 5100 Aachen Kiesewetter | Meßeinrichtung zur Messung des Verformungsvermögens von roten Blutkörperchen |
US4525666A (en) * | 1982-05-03 | 1985-06-25 | Coulter Electronics, Inc. | Cell breakdown |
GB8408529D0 (en) | 1984-04-03 | 1984-05-16 | Health Lab Service Board | Concentration of biological particles |
US4791355A (en) | 1986-10-21 | 1988-12-13 | Coulter Electronics Inc. | Particle analyzer for measuring the resistance and reactance of a particle |
US5223398A (en) | 1987-03-13 | 1993-06-29 | Coulter Corporation | Method for screening cells or formed bodies for enumeration of populations expressing selected characteristics |
US5006460A (en) | 1988-05-26 | 1991-04-09 | Pantox Corporation | Method for measuring DNA damage in single cells |
US5548661A (en) | 1991-07-12 | 1996-08-20 | Price; Jeffrey H. | Operator independent image cytometer |
US5532139A (en) | 1992-10-30 | 1996-07-02 | Micro-Med, Inc. | Micro lysis-analysis process to measure cell characteristics and diagnose diseases |
US5610027A (en) | 1992-10-30 | 1997-03-11 | Micro-Med, Inc. | Microphoto lysis-anlaysis process to measure cell characteristics |
US5595866A (en) * | 1994-05-27 | 1997-01-21 | Methodist Hospital Of Indiana, Inc. | Step-wise method to remove cryoprotectant from sperm |
-
1995
- 1995-12-29 GB GBGB9526684.7A patent/GB9526684D0/en active Pending
-
1996
- 1996-12-27 CA CA002240471A patent/CA2240471C/en not_active Expired - Lifetime
- 1996-12-27 WO PCT/GB1996/003256 patent/WO1997024598A1/en active IP Right Grant
- 1996-12-27 DE DE69622282T patent/DE69622282T2/de not_active Expired - Lifetime
- 1996-12-27 AT AT96944116T patent/ATE220454T1/de not_active IP Right Cessation
- 1996-12-27 EP EP96944116A patent/EP0870184B1/en not_active Expired - Lifetime
- 1996-12-27 AU AU13846/97A patent/AU714947B2/en not_active Expired
- 1996-12-27 JP JP52411597A patent/JP3650128B2/ja not_active Expired - Lifetime
- 1996-12-27 US US09/101,005 patent/US6668229B1/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007527540A (ja) * | 2004-03-05 | 2007-09-27 | ザ・リサーチ・ファンデーション・オブ・ステート・ユニバーシティ・オブ・ニューヨーク | 細胞の体積変化を測定するための方法及び装置 |
Also Published As
Publication number | Publication date |
---|---|
AU714947B2 (en) | 2000-01-13 |
GB9526684D0 (en) | 1996-02-28 |
AU1384697A (en) | 1997-07-28 |
DE69622282T2 (de) | 2002-11-21 |
DE69622282D1 (de) | 2002-08-14 |
US6668229B1 (en) | 2003-12-23 |
JP3650128B2 (ja) | 2005-05-18 |
WO1997024598A1 (en) | 1997-07-10 |
ATE220454T1 (de) | 2002-07-15 |
CA2240471C (en) | 2004-11-30 |
CA2240471A1 (en) | 1997-07-10 |
EP0870184B1 (en) | 2002-07-10 |
EP0870184A1 (en) | 1998-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7621192B2 (en) | Medical device durability test apparatus having an integrated particle counter and method of use | |
Hardeman et al. | Laser-assisted optical rotational cell analyser (LORCA); I. A new instrument for measurement of various structural hemorheological parameters | |
Valberg et al. | Magnetic particle motions within living cells. Measurement of cytoplasmic viscosity and motile activity | |
TR201901203T4 (tr) | Kan numunelerindeki parçacık analizi için akış hücresi sistemleri ve yöntemleri. | |
Markle et al. | Force relaxation and permanent deformation of erythrocyte membrane | |
US4374644A (en) | Blood cell volume monitoring | |
JP2000503115A (ja) | 細胞サンプルの試験方法 | |
JP4160117B2 (ja) | 細胞サンプルを試験するための方法 | |
JP2002315598A (ja) | 濾過器を用いた粒子の計装処理方法並びにその装置 | |
JPH034863B2 (ja) | ||
Jones et al. | Evaluation of the contribution of red and white cells to the flow of suspensions of washed blood cells through 3 μm Nuclepore membranes | |
Cooley-Lock et al. | Assessment of erythrocyte damage and in-line pressure changes associated with simulated transfusion of canine blood through microaggregate filters | |
US20210341371A1 (en) | Cell scanning technologies and methods of use thereof | |
Lewis | Quality Control: Quality Control in Haematology | |
Urdahl | COBE Spectra® apheresis system: designs, protocols and results | |
Eppihimer et al. | The mean filtration pressure of leukocyte suspensions and its relation to the passage of leukocytes through nuclepore filters and capillary networks | |
Seiffge et al. | Passage time of red blood cells in the SER; their distribution and influences of various extrinsic and intrinsic factors | |
Chung et al. | Assessing erythrocyte filterability with 3 μm pore size polycarbonate membranes at constant cell flux | |
EP4286827A1 (en) | Quality control substance used in urine sediment analyzer | |
Eisert et al. | Current problems and results in testing microaggregate filters | |
Paarup et al. | Performance characteristics of thromboelastometry assays using incompletely filled and prolonged stored samples | |
Saure et al. | Is it possible to estimate the Morphology Score of Platelets stored for Transfusion by Volume-Determination with an optical Cell Counter? Optical Cell Sizing and Platelet Morphology | |
RU2582285C2 (ru) | Способ оценки эффективности микрофильтрующих устройств, предназначенных для переливания крови и ее компонентов | |
JPH0256624B2 (ja) | ||
Gao et al. | Blood cell filtration test at low flow rates for clinical applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20031226 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20031226 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050118 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050217 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080225 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090225 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100225 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100225 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110225 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120225 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120225 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130225 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130225 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140225 Year of fee payment: 9 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |